Show simple item record

dc.contributor.authorGarden, GA
dc.contributor.authorMoss, GB
dc.contributor.authorEmonyi, W
dc.contributor.authorBwayo, J
dc.contributor.authorVelentgas, P
dc.contributor.authorKreiss, J
dc.date.accessioned2013-10-18T08:51:07Z
dc.date.available2013-10-18T08:51:07Z
dc.date.issued1993
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/8427903
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/57711
dc.description.abstractSerum beta-2 microglobulin (beta 2-M) has prognostic value similar to lymphocyte profiles for predicting disease progression in those infected with the human immunodeficiency virus (HIV). However, the relationship between beta 2-M and HIV disease progression among inhabitants of countries with endemic tropical diseases has not been evaluated. To determine the relationship between serum beta 2-M levels and HIV infection and disease status in an African population, serum beta 2-M levels were measured in 369 patients attending a sexually transmitted disease (STD) clinic in Nairobi, Kenya. Mean serum beta 2-M was significantly higher in HIV seropositive than in HIV seronegative individuals. Among HIV infected patients, higher mean beta 2-M levels were observed in those with HIV associated symptoms or laboratory markers of advanced HIV disease. Significant inverse correlations between beta 2-M and the percentage of CD4 lymphocytes or CD4/CD8 ratio were found. These findings suggest that beta 2-M measurements may have prognostic value for HIV infected populations in developing countries.en
dc.language.isoenen
dc.titleBeta-2 microglobulin as a marker of HIV disease status in Nairobi, Kenya.en
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record